Skip to content

Latest

Novartis announces FDA approval of Gilenya

Novartis announces FDA approval of Gilenya

Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Gilenya (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis, making it the first disease-modifying therapy indicated for these patients.

Metro completes Coutu acquisition

Metro completes Coutu acquisition

Metro Inc. has completed its $4.5 billion ($3.6 billion U.S.) acquisition of the Jean Coutu Group, creating a food and drug retailer with more than  1,300 stores in Quebec, Ontario and New Brunswick.

PANTHERx selected by Otsuka to distribute Jynarque

PANTHERx selected by Otsuka to distribute Jynarque

PANTHERx Specialty Pharmacy has been selected by Otsuka America Pharmaceutical, Inc.  to distribute Jynarque (tolvaptan), the only FDA-approved therapy for patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD).

Digital health consumers recasting the market

Digital health consumers recasting the market

As of 2017, 45% of the global population was using the internet, and it is projected that 76% will have access by 2030, according to Euromonitor International. With more connectivity, a new type of connected consumer is rising: the digital health consumer.

Understanding Amazon’s impact on drug retailing

Understanding Amazon’s impact on drug retailing

Who knew that the ancient Greek philosopher Heraclitus would sum up Amazon.com’s influence on our modern health care industry so well? “The only constant is change,” he is said to have uttered, along with “You cannot step twice into the same river.